

Annual Report

2025

The central resource for
the Swiss biotech industry



Credits

Publisher: Swiss Biotech Association
Concept and text: Sabine Bamert, Michael Altorfer, Swiss Biotech Association
Layout: Thomas Schicker Konzeption und Gestaltung, Zürich
Pictures: Swiss Biotech Association
Print: Schmid-Fehr AG
Climate-neutral print on wood-free, matt coated paper



Contents

Growth fueled by investment, innovation and collaboration	4
Record membership and Swiss Biotech Day expansion	5
Highlights of the Swiss Biotech Association in 2025	6
Swiss Biotech Ventures: Financing and partnering	8
Swiss Biotech Orbit: Matching talent and opportunities	9
Development in numbers	10
The Swiss Biotech Association	
Our stakeholders: Who we support and represent	11
Our mission: Representing the interests of the industry	12
Empowering biotechs: Support across essential areas	13
Our powerful platforms: How we bring our mission to life	14
Promoting accomplishments of the industry	16
Swiss Biotech Success Stories	18
In the media	24
Partner network	26
Financial statements 2025 & 2024	28
Focus on what really matters	31
Preferential business solutions for our members	34
Swiss Biotech Association board and management	36
Supporting the Swiss biotech hub: Objectives 2026	38
Our members	40

Growth fueled by investment, innovation and collaboration



In another year marked by global uncertainty, the biotech industry has again demonstrated its resilience and continued expansion. Despite ongoing challenges, it has maintained Switzerland's reputation as a reliable and stable partner. The Swiss Biotech Association is dedicated to protecting this position by providing a unified voice for the ecosystem, promoting science, fostering collaborations and entrepreneurship.

Financial performance and investments

As capital markets rebound, 2025 saw several major financings that reflect confidence in Swiss biotech. MoonLake secured CHF 500 million for their late-stage immunology asset, Windward raised CHF 200 million to develop its asthma pipeline, and GlycoEra closed a CHF 130 million round to accelerate targeted protein degradation. Additional financings included e.g. ADC Therapeutics, Oculis, Idorsia, RhyGaze, Nuclidium, Haya, Cutiss, and Numab. These investments highlight the diversity of innovation across different modalities and disease areas within the community. BioVersys' IPO was a notable milestone, showcasing that SIX offers an attractive alternative to NASDAQ for certain companies.

Partnerships and collaborations

Strategic dealmaking further emphasized the strength of Switzerland's biotech ecosystem and the quality of its scientific breakthroughs. Araris advanced the ADC field through a new partnership; CDR-Life and Neurimmune expanded their respective partnerships with Boehringer Ingelheim and AstraZeneca; Windward expanded its pipeline through a significant in-licensing agreement. These accomplishments demonstrate the international trust placed in Swiss innovation.

Association initiatives

The Swiss Biotech Association continues to tailor its initiatives to the evolving needs of its members, notably through events

such as the Swiss Biotech Day, and peer-to-peer meetings for CEOs, CFOs, and HR leaders. The association expresses its gratitude to all participants for their valuable discussions and contributions to shaping the SBA agenda. Collaboration with Swissmedic is ongoing to improve the clinical trial environment, and engagement with Life Science Cares underscores the belief that biotech success must be accompanied by social responsibility.

Looking ahead

Switzerland remains exceptionally well positioned for the future. By combining scientific rigor, entrepreneurial spirit, and trusted partnerships, the community is ready to lead the next era of global biotech innovation. The Swiss Biotech Association looks forward to welcoming attendees at Swiss Biotech Day on May 4–5, where our general assembly will be held and Matthias Fehr, Head Private Equity at HBM Partners, will be proposed for election to the board, strengthening connectivity to the investor community and continuing the shared mission to drive the success of the Swiss biotech industry.

Sincerely yours,

A handwritten signature in blue ink, appearing to read 'P. Amstutz'. The signature is fluid and cursive, written over a white background.

Patrick Amstutz
President Swiss Biotech Association

Record membership and Swiss Biotech Day expansion



As the Swiss biotech industry continued to expand, Swiss biotech companies invested CHF 2.6 billion in their R&D pipeline, while attracting new funds of CHF 2.5 billion, according to the Swiss Biotech Report 2025. Our association also expanded strongly, with 130 new members joining in 2025 alone. The Swiss Biotech Day grew by another 30%, assembling more than 3,000 biotech leaders from 49 countries.

The Swiss biotech hub is clearly recognized as a global innovation center and a key global collaboration partner. In 2025, WIPO has ranked Switzerland at the top of the Global Innovation Index for the 15th consecutive year. The Swiss Biotech Day established itself as one of the leading global biotech conferences while the Swiss biotech hub has proven its resilience.

As outlined in the Swiss Biotech Report 2025, privately financed Swiss biotech companies attracted a record level of new investments (over CHF 800 million or USD 1 billion, respectively), while the global sentiment for biotech investments remained subdued.

With 659 members at the end of 2025, the association reached a new record as its expansion further accelerated. We very much appreciate this positive feedback and sign of trust as it offers us greater financial flexibility and strengthens our credibility with policymakers and international partners.

In 2025, we used this support to:

- ✓ Further optimize the global biotech framework through our collaborations with Interpharma, scienceindustries, economiesuisse and the International Council of Biotech Associations
- ✓ Promote the Swiss biotech hub as an attractive partner for international collaborations and strengthen international alliances, such as the Eureka network for non-dilutive funding or the Access Consortium for joint drug approvals by Australia, Canada, Switzerland, Singapore and the UK

- ✓ Promote the value and contribution of the Swiss biotech industry, honoring Pascale Vonmont and Henri B. Meier with the Swiss Biotech Success Stories Award
- ✓ Establish peer-to-peer meetings in the Swiss biotech community to connect CEOs, CFOs and Swiss biotech HR leaders in dedicated groups
- ✓ Accelerate onboarding to the Swiss biotech ventures and talent platforms
- ✓ Support the formation of broadly diversified biotech/deep tech funds offering attractive investment opportunities for new investor groups, such as pension funds

Our objectives for 2026 are outlined on pages 38–39. For example, we plan to further expand our peer-to-peer networking platforms by organizing the first Swiss biotech meetings for chief scientific and medical officers (CSO, CMO) and for chemistry, manufacturing and quality control (CMC) specialists.

Please reach out to our board members and the management team (p. 36–37) if you would like to share feedback, advice and ideas on how to promote and further strengthen the Swiss biotech industry.

Yours faithfully,

Michael Altorfer
CEO

Highlights of the Swiss Biotech Association in 2025



Since 2021, the **Swiss Biotech Day** has expanded by an average of 30 percent each year. It has become a premier global biotechnology conference for life sciences professionals, fostering international collaboration and impactful partnerships. In 2025, it attracted more than 3,000 participants from 49 countries, including 25 international delegations. It was by far the biggest and most international edition of the Swiss Biotech Day.

Our **Swiss Biotech Report 2025**, outlined capital investments in Swiss biotech companies of CHF 2.5 billion and R&D investments aggregating to CHF 2.6 billion.

Switzerland's most comprehensive **Swiss Biotech Directory** with over 1,600 company entries was printed and distributed to stakeholders in Switzerland and at leading international biotech conferences.

Our **platforms supporting all Swiss biotech companies** continue to grow: Swiss Biotech Ventures for funding, Global Village for international collaboration, and Swiss Biotech Orbit for talent acquisition.

We represented the Swiss biotech industry in the International Council of Biotechnology Associations' (ICBA).

We supported the ICBA **in talks with the WHO, WTO, and WIPO**, by emphasizing the needs of innovative biotech startups and SMEs.

Swiss biotech companies and the association were presented in the **Swiss pavilions at BIO International and BIO Europe**, at Sachs Associates' investor conferences, Ilmac, and many more.

At our general assembly, **Madiha Derouazi and David Urech were elected as new board members**. At the same time, the board expressed its appreciation for the contributions and support of Jurgi Camblong, who did not stand for re-election.



At the Swiss biotech CFO meeting last fall, CFOs and finance specialists discussed their specific requirements and challenges at SIX Swiss Exchange in Zürich.

The Swiss biotech **CEO meeting**, as well as the **CFO and HR leaders meetings**, bring executives together to discuss their specific challenges in a relaxed and interactive setting. These gatherings foster collaboration, helping to shape effective frameworks for peer exchange, set priorities and address strategic issues.

In 2026, additional **peer-to-peer meetings** for chief scientific and medical officers (**CSO, CMO**) and for chemistry, manufacturing and quality control (**CMC**) specialists will provide platforms to discuss best practices, for example on optimizing the outsourcing of manufacturing or exploring R&D trends in translational medicine.



The Swiss biotech HR leaders meeting was held in November 2025 at Debiopharm in Lausanne, focusing on leadership, talent management and business culture in the biotech industry.

Swiss Biotech Ventures platform

Swiss biotech companies, global biotech investors and industry partners equally benefit from the Swiss Biotech Ventures platform. It is free of charge and matches Swiss biotech companies, global biotech investors, and industry partners to facilitate financing, licensing and research collaborations.

With the Swiss Biotech Ventures platform, the Swiss Biotech Association enables Swiss biotech companies to present their investment and partnership opportunities to global biotech investors and multinational pharma and industry partners. Investors, family offices, foundations and pharmaceutical companies gain insight into the pipeline of the Swiss biotech hub, and easily discover and contact companies matching their strategic focus based on modalities, indications, and development stage.

Swiss Biotech Ventures is a comprehensive database that creates transparency between stakeholders. On the “sell side”, Swiss biotech companies describe their value proposition. On the “buy side”, global biotech investors and pharmaceutical representatives identify investment and partnership opportunities matching with their selection criteria. Both sides present their focus and goals, rendering matchmaking between these players efficient and transparent.

Swiss Biotech Ventures is steadily growing. At the beginning of 2026, more than 1,000 investors and pharmaceutical companies were listed, and about 270 innovative venture projects from Swiss biotech companies were presented. Every time a venture matching the selection criteria of an investor is added, or its status changes (e.g. from preclinical to clinical phase I), interested parties receive an email notification and can find out more on the platform.

Both sides gain valuable time as individual communication on the project development is replaced by timely, transparent and consistent information. In the Swiss tradition, the Swiss Biotech Association takes a neutral stance. No company is promoted,

nor privileged information is shared with any of the parties, nor does the Swiss Biotech Association receive any success fee. Anyone on the platform has free access to identical information, simultaneously, transparently and to the benefit of all parties.

In conjunction with the Swiss Biotech Ventures platform, the Swiss Biotech Association also helps companies to present and partner at the Swiss Biotech Day and at national and international events. Quarterly highlight reports from the Swiss biotech industry with background information complete the offering.



Join Swiss Biotech Ventures and gain access to:

- ▶ free of charge platform, by invitation only
- ▶ matching Swiss biotech companies with global biotech investors and industry partners to facilitate financing, licensing and research collaboration
- ▶ timely, transparent, simultaneous, and consistent information
- ▶ a steadily growing database of thriving biotech ventures
- ▶ free newsletters on Swiss biotech venture highlights and background information



Use this QR code to register on Swiss Biotech Ventures and promote the platform amongst your peers around the globe

Swiss Biotech Orbit: Matching talent and opportunities



Bridging talents to biotech brilliance

The Orbit platform is available to biotech talent in Switzerland and abroad. Biotech companies in Switzerland can use the platform to search this talent pool without the need to publicly publish open positions.

Swiss Biotech Orbit helps to match job opportunities and talents, and supports all Swiss biotech companies that can offer job opportunities.



The Orbit platform features a wide range of local talent, with searching and filtering tools to help you find the right person for the job.

David Pejoski, Co-founder and Co-CEO, Adoram Therapeutics

Rapidly expanding

The non-public Swiss Biotech Orbit talent platform matches the skills of talents with the criteria of job offers. Since its launch, numerous life science companies and talents have joined, and more are joining every day, contributing to the rapid expansion of the platform.

Swiss Biotech Orbit opens doors to exciting opportunities for professionals, and future talents in life sciences R&D, and supports Swiss biotech companies in identifying the right talent in the industry.

**SWISS+
BIOTECH™**
Orbit

How to get involved

Swiss Biotech Orbit can only be successful with the support of our members and other stakeholders in the industry. We encourage you to join Swiss Biotech Orbit and contribute to the growth of the life science industry in Switzerland.



Use this QR code to match talents and opportunities

Development in numbers

At the end of 2025, the Swiss Biotech Association counted a record number of 659 members. Our website, newsletters, social media activities and mailings provide an up-to-date and comprehensive overview of developments in the Swiss biotech industry. The number of members, subscribers and website visitors continues to grow steadily.



The Swiss Biotech Association


Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access

to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.



Our stakeholders: Who we support and represent

The Swiss Biotech Directory lists almost 1,700 companies, reflecting both the rapid growth, as well as the diversity of this vibrant economic sector. The Swiss biotech industry has built one of the most densely populated and comprehensive biotech ecosystems worldwide.




Highly specialized clinical research organizations, manufacturers, suppliers and technical consultants complement, support, and advise biotech companies which focus on the development of their proprietary product pipelines.

Many of the globally leading CROs and suppliers have selected Switzerland as their international headquarter, and Swiss biotech

companies benefit from the proximity of Roche and Novartis and numerous international pharma companies. Increasingly, international companies select Switzerland as their hub for the production of highly complex biologics, peptides and cell products. International investors and industry specialists alike, value the numerous advantages Switzerland offers.

Our mission: Representing the interests of the industry

The Swiss Biotech Association is a non-profit, member-driven organization representing the interests of the Swiss biotech industry. Swiss biotech companies are leading the way in developing and commercializing innovative medicines, diagnostics, healthcare treatments, services and enabling technologies.



Our core objective is to ensure that the value generated by the Swiss biotech industry continues to grow and that the industry contributes to the well-being of the socio-economic ecosystem thereby enabling Switzerland to be a key player at the forefront of bioscience innovation. To this end, the Swiss Biotech Association is dedicated to supporting Swiss biotech companies through the following:

Developing favorable and competitive framework conditions

- ▶ Creating awareness of the biotech industry's needs and interests with policy makers
- ▶ Advocating a competitive tax system alongside lean and pragmatic regulations
- ▶ Fostering life science education, technology transfer and intellectual property

Attracting talent, know-how and financial resources to drive innovation and growth

- ▶ Promoting and facilitating access to funding opportunities
- ▶ Connecting investors and attractive biotech investment opportunities
- ▶ Facilitating access to national and international talent

Fostering networking through strategic, national and international partnerships

- ▶ Connecting industry stakeholders and life science clusters
- ▶ Organizing and co-promoting national and international life science events
- ▶ Providing access to privileged information through industry platforms and working groups


Promoting the accomplishments of the Swiss biotech industry

- ▶ Disseminating the value-creation of Swiss biotech companies
- ▶ Visualizing the diversity and competitiveness of Swiss biotech companies
- ▶ Presenting innovative products and technologies and their contribution to quality of life



Empowering biotechs: Support across essential areas

Biotech industry segments



Our powerful platforms: How we bring our mission to life

The Swiss Biotech Association creates platforms that benefit all Swiss biotech companies – not only its members – in financing and partnering, talent, education, branding and networking. We bring people together to shape ideal framework conditions for a vibrant Swiss biotech community and beyond.



Boosting global visibility

By promoting biotechs in the Swiss Biotech Directory, by disseminating their news, and with success stories



Financing and partnering

By connecting Swiss R&D biotech companies with global investors and industry partners on Swiss Biotech Ventures



Finding talent internationally

By matching Swiss job opportunities and talents on Swiss Biotech Orbit




Foster International collaboration

By uniting foreign biotech clusters with the Swiss biotech ecosystem through our Global Village



Professional development and education

Offered at the Swiss Biotech Association Academy by academic institutions & regular Swiss Biotech Insight meetings



Our event platforms offer networking opportunities for executives and professionals to discuss their needs in a relaxed, peer-to-peer setting. In a fast-evolving industry, face-to-face interactions accelerate innovation, strengthen partnerships and shape the future of the Swiss biotech community.



Swiss Biotech Day

For international networking at one of the leading global biotech conferences, with thousands of guests

Swiss biotech CEO meetings

The exclusive and informal networking event for Swiss R&D biotech CEOs

Swiss biotech CFO meetings

To openly share and discuss unique requirements as a CFO in the biotech sector

Swiss biotech CMC/quality control meetings

Enable CMC specialists to exchange experiences, avoid pitfalls and optimize manufacturing outsourcing

Swiss biotech CSO/CMO meetings

Gathering Swiss biotech CSOs to discuss R&D trends in translational medicine and share best practices

Swiss biotech HR leaders meetings

A day to shape business culture, leadership, and talent management in the biotech industry



Promoting accomplishments of the industry

The Swiss Biotech Association highlights the vital contribution of the biotech industry in Switzerland and abroad, positioning it as a key economic pillar. In addition to the Swiss Biotech Success Stories (see p. 18-23) and our digital platforms (see p. 14), our digital media and publications play a crucial role in expanding our impact as the central resource for the Swiss biotech industry.

The screenshot displays the Swiss Biotech Association website. At the top left is the logo 'SWISS BIOTECH' with a red cross icon. To the right are links for 'Log in or Register' and a search icon. The main content area is divided into two sections: 'Industry news' and 'Our featured events & more'. The 'Industry news' section features a large banner for 'SWISS BIOTECH Global Village' with the tagline 'CREATE LASTING BUSINESS TIES' and 'Connect with the Swiss biotech ecosystem'. Below the banner are four news items, each with a date and a 'More' button: 'Invest in Swiss Biotech' (The global biotech ventures platform), 'Unite Talent & Opportunities' (Swiss Biotech Orbit platform), 'Collaborate with Swiss Biotech' (Worldwide networking), and 'Get the Insight' (Swiss Biotech Report 2025). The 'Industry news' list includes: 'Beware of fraudulent emails impersonating the Swiss Biotech Association' (October 8, 2024), 'leadXpro and Nuclera partner for complex membrane proteins' (February 17, 2026), 'InSphero and PharmaNest: Partnership to advance translational fibrosis research' (February 11, 2026), 'Industry leaders form alliance for microphysiological systems' (February 10, 2026), 'Akceso Advisors elects Seng Chin Mah as board member' (February 10, 2026), 'abc biopply: New organoid competence center in Basel' (February 5, 2026), and 'Cosmo: Substantial private placement with Capital Group' (February 3, 2026). The 'Our featured events & more' section shows two event cards: 'Swiss Biotech Day' (May 4-5, 2026, Basel) and 'SWISS Pavilion at BIO Asia-Taiwan 2026' (July 15-19, 2026, Taipei City, Taiwan). Each event card includes a host name and a heart icon for favoriting.

swissbiotech.org is a valuable information source for the industry, offering an up-to-date and comprehensive view of the Swiss biotech sector. This is reflected in a steadily growing number of website visitors.



The newsletter from the central resource for the Swiss biotech industry

July 2025

Why supporting Life Science Cares matters - Bill Burns, Ambassador

Act locally to really make a difference

In his video statement, Bill Burns, former Roche Pharma CEO, biotech board leader, and AMR Action Fund Chair, with 40+ years in life sciences shares his perspective on why supporting Life Science Cares Switzerland and the charitable projects they champion is so meaningful.






Volunteer with Life Science Cares Switzerland
Make a difference

Life Science Cares Switzerland turns corporate social responsibility into real-world impact. Employees of your company can register for meaningful volunteering opportunities - whether it's collecting and delivering surplus food, assisting people with a minimal education level with writing and admin tasks, or helping organize a charitable Christmas event. [Apply now](#)

Major transactions, funding, mergers and acquisitions

First quarter highlights in the Swiss biotech industry at a glance

Below info graph summarizes a selection of highlights in the Swiss biotech industry of this year's first quarter. For more info, just click on the info graph.



With our monthly newsletter you stay ahead in the dynamic biotech landscape with the latest industry insights and opportunities

Our print publications are distributed at events and by direct mailings

SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements

Swiss Biotech Success Stories demonstrate the power and potential of the industry

The Swiss Biotech Success Stories Awards recognize valuable accomplishments and honor those who have made important and sustainable contributions to the biotech industry in Switzerland. The awards are presented each year at the Swiss Biotech Day and reflect the diversity and achievements of this innovative sector.



Switzerland is one of the world's leading biotech hubs and attracts many foreign companies, specialists and investors. It provides over 60,000 jobs and, together with the pharmaceutical and chemical industries, accounts for almost half of Swiss exports.

To make the industry's impact more visible, the Swiss Biotech Success Stories initiative was launched in 2018. Selected success stories are showcased to illustrate how Swiss biotech companies help patients, improve health care worldwide, and make a valuable and significant contribution to the Swiss and global economy.

Laureates are individuals or groups who have earned extraordinary merits. Success is broadly defined as scientific, translational,

medical or commercial, together with other aspects that have a positive impact on the biotech and life science industry and society in Switzerland.

"It is essential to share with the public the importance and success factors of biotech companies and ensure that decision-makers understand what it takes for the industry to develop and remain competitive," says Michael Altorfer, CEO of the Swiss Biotech Association. "Young talent should be inspired and motivated to take a closer look at the great variety of career profiles in biotech."

12 success categories

- ▶ Completed achievement with lasting impact
- ▶ Scientific breakthrough
- ▶ New technology
- ▶ Strong impact on society
- ▶ Product approval and sustainable revenues
- ▶ Important IP, innovative deal-making, acquisition
- ▶ Involvement of one or more Swiss citizens
- ▶ Swiss-based company / institution
- ▶ Creation of jobs in Switzerland
- ▶ Other aspect with a direct link to Switzerland
- ▶ Enabler for the biotech industry
- ▶ Swissness: Think global, made in Switzerland



An independent jury of experts annually selects the Swiss Biotech Success Stories winners



Jürg Zürcher

President of the jury
Independent biotechnology
leader and expert



Igor Fisch

President Fongit
CEO & Co-Founder New
Biologix




**Stefanie Flückiger-
Mangual**

CEO and Co-Founder
Tolremo



Gabrielle Gache

CEO at Sappiens
Founder at Neixora
Partners



Gabriela Güntherodt

EY Partner & Biotech
Sector Leader
Switzerland/Europe West



Chandra P. Leo

Investment Advisor
Private Equity HBM
Partners



Daniela Marino

CEO and Co-Founder
Cutiss



Thomas Staffelbach

Secretary of the jury
TS Kommunikation

A big thank you to our sponsor:



The Swiss Biotech Success Stories Awards are also supported by:

**WISSENSCHAFT.
BEWEGEN**
GEBERT RUF STIFTUNG

| Basel-Stadt | TS Kommunikation

SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements



- ▶ Headquartered in Allschwil, Actelion is part of the Johnson & Johnson Family of Companies. Its ground-breaking research and medicines have been a key contributor to improve the lives of people affected by pulmonary hypertension, and made Actelion an industry leader in this area.



Werner
Arber

- ▶ Prof. Dr. Werner Arber, Swiss microbiologist and geneticist, won the 1978 Nobel Prize in Physiology or Medicine for his discovery of restriction endonucleases. His groundbreaking research in the field of molecular genetics was instrumental in the development of biotechnology.



- ▶ Bachem situated in Bubendorf is a leading company specializing in development and manufacture of peptides and oligonucleotides. With over 50 years of experience and expertise, Bachem provides products and services for research, clinical development and commercial application to pharmaceutical and biotechnology companies globally.



- ▶ Basilea Pharmaceutica in Allschwil is a biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives. They are committed to developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions.



- ▶ Biogen in Baar is a leading biotechnology company that pioneers innovative science and delivers new medicines to transform patient's lives. A broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy and the state-of-the-art biologics manufacturing facility in Luterbach are proof of Biogen's pioneering approach.



- ▶ Family-owned Debiopharm from Lausanne, identifies high-potential compounds in oncology and for the treatment of bacterial infections. They are tested in clinical development and licensed to business partners globally. Millions of patients benefit from their therapies every year.



▶ ESBATEch, now a Novartis company, is recognized for its pioneering role in developing single-chain antibody fragments for ophthalmic indications. The most advanced product from the ESBATEch platform received market approval by the FDA in October 2019 and shortly thereafter in all major markets.



▶ The foundation promotes scientific research on neuromuscular diseases (myopathies) affecting children and adults. It awards grants to young researchers and has provided seed funding for two startups. It has established a scientific forum to encourage exchange of ideas, and also supports centers which care for patients.



▶ Genedata, global market leader for software solutions that digitalize data-rich and complex bio-pharmaceutical R&D processes, enables an R&D revolution driven by precision medicines and artificial intelligence approaches. It helps the industry to deliver innovative biotherapeutics, vaccines and cell & gene therapies faster.



▶ The Schlieren-based company is an integral part of Roche Pharmaceutical Research and Early Development since 2005, and a pioneer in antibody engineering in cancer immunotherapy. Its antibody glycosylation technology increases immune-mediated cancer cell killing and builds the basis for improved cancer medicines.



▶ Helsinn, an important employer in Ticino, has a broad portfolio of marketed cancer care products and a deep development pipeline. It has built significant R&D and manufacturing capacities, also advances patient care and supports healthcare innovation with its investment fund.



▶ Humabs BioMed, subsidiary of Vir Biotechnology, uses its immunologic expertise and cutting-edge technology to combat infectious diseases and other serious conditions. They are a pioneer in the discovery, engineering, and development of human monoclonal antibodies, e.g. crucial for fighting Ebola and COVID-19, and have helped transform the infectious disease landscape.

SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements



Etienne
Jornod

- ▶ Etienne Jornod, Swiss entrepreneur, was Executive Chairman of the Vifor-Galenica Group delivering 25 consecutive double-digit net profit growth, supporting millions of patients and creating thousands of jobs. In 2020, he acquired OM Pharma with friends, aiming to create a unique biopharmaceutical company based on bacteria lysates expertise.

Lonza

- ▶ Lonza is one of the world's largest healthcare manufacturing organizations, serving pharmaceutical, biotech and nutritional markets. Lonza's work enables its customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.



Henri B.
Meier

- ▶ Dr. Dr. h.c. Henri B. Meier's career spans decades, combining experience in economic development, healthcare, finance, and entrepreneurship. His work has significantly influenced the venture capital landscape in Switzerland and globally, particularly in the healthcare and biotech sectors.



- ▶ Founded by the renowned immunologist, Professor Bernard Mach MD PhD, privately-owned Novimmune is a leading light in the discovery and development of fully-human, antibody-based drugs used to fight autoimmune and inflammatory diseases and cancer.



- ▶ Fully integrated into GlaxoSmithKline since 2013, Okairos from Basel developed innovative T-cell based vaccines for major infectious diseases such as malaria, hepatitis C, HIV, and Ebola. Its novel replication-incompetent adenovirus vectors could enable the development of important new vaccines and offer immunizations against illnesses that lack vaccines.



- ▶ The advanced technologies in protein expression by Selexis, based in Plan-les-Ouates, provide biotech and pharmaceutical companies a rapid, stable, and cost-effective solution for the production of recombinant proteins. In 2017, Selexis was acquired by JSR and integrated into KBI Biopharma in 2023.



- ▶ SOPHiA GENETICS generates clinically actionable insights and improved patient outcomes from a global data-sharing network. They democratize data-driven medicine globally through a cloud-based, decentralized SaaS platform, empowering shared insights among clinicians and researchers, and aiming for equal access to knowledge and improved clinical outcomes.



Hans-Peter Strebel

- ▶ Dr. Hans-Peter Strebel founded Fumapharm AG with three other scientists in 1983. Its successful research led to the development of Tecfidera, a disease modifying therapy for relapsing multiple sclerosis (MS). More than 600,000 patients worldwide have already benefited from the therapy.



- ▶ The trio of foundations has been supporting biotech startups with great success thereby making a significant contribution to the growth of the Swiss biotech industry. They share the nomination for the Swiss Biotech Success Stories Award.



- ▶ This transformational joint venture provides Vifor Pharma direct access to dialysis patients, facilitating the product distribution and recruitment for clinical development. It transformed the company from Glattbrugg rapidly into a global nephrology corporation. Such vertical integration is a role model for the convergence of different life science sectors.



Pascale Vonmont

- ▶ For over 25 years, Dr. Pascale Vonmont has been a driving force in advancing innovation and entrepreneurship. As a passionate bridge-builder between science, business, and society, she is committed to accelerating knowledge transfer and ensuring that groundbreaking research translates into real-world applications.



Use this QR code to find more information about the Swiss Biotech Success Stories

In the media

National and international coverage of the Swiss biotech industry's achievements helps highlight the value of its research contributions, products and technologies.

The collage features several key articles and reports:

- BioXconomy:** "Switzerland roots its foundations in life sciences collaboration" (October 13, 2025). The article highlights Switzerland's position as Europe's biotech partnership hub, attracting \$3.1 billion in life sciences investment.
- BioBiz Buzz:** "4. The Power of International Alliances: Unpacking the Swiss Biotech Report 2025" (May 14, 2025). The episode discusses the findings and implications of the Swiss Biotech 2025 report, focusing on the power of international alliances and cross-border collaborations.
- LE TEMPS:** "Les levées de fonds pour les biotechs ont augmenté en 2024, mais toutes n'en bénéficient pas" (May 19, 2025). The article notes that while funding for biotech startups increased in 2024 by 22%, the situation remains complex.
- ClinicalTrials Arena:** "Power of collaboration more pertinent than ever says pharma experts" (May 19, 2025). This analysis piece discusses a recent gathering of experts who underscored the power of international alliances in the Swiss biotech sector.
- Yahoo Finance:** "Swiss biotech sector's R&D investment grew in 2024 despite global trends" (May 19, 2025). The article reports that R&D investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles.
- NZZ:** "Die Schweizer Biotechindustrie gibt sich trotz Gegenwind aus den USA zuversichtlich" (May 19, 2025). The article states that 70% of biotech employees in Switzerland are confident about the industry's future, despite competition from the USA and China.
- Portale PMI per piccole e medie imprese:** "Aumento degli investimenti nelle biotecnologie svizzere" (May 19, 2025). This report notes a significant increase in R&D investment in Swiss biotech, with a 39% increase in 2024 compared to the previous year.
- 한국무역신문 (Korea Trade Information):** "K-Biohealth Strengthens Global Cooperation at Switzerland, Europe's Bio Hub" (May 19, 2025). This article covers the Korea-Switzerland Biohealth Partnership Forum 2025, highlighting strengthened cooperation between the two countries.

SWISS BIOTECH DAY 2027

© Swiss Biotech Association

April 26–27, 2027
Congress Center Basel

What you can expect:

- › Welcome reception on April 25
- › Meet over 3,000 senior experts from the life science industry
- › More than 130 exhibitors and the Global Village with international delegations from all over the world
- › Innovative biotech start-ups and medium-sized biotech companies
- › Thematic company pitching sessions and panel discussions
- › Swiss Biotech Success Stories Awards
- › Swiss Biotech Report 2027
- › Pre-scheduled one-to-one partnering meetings
- › General Assembly of the Swiss Biotech Association



Sign in on our website at
swissbiotechday.ch
and stay updated about any news.

Host & event manager:

Logistics & marketing partner:

Partner network provides crucial advantages

The Swiss Biotech Association can reap several benefits from forming partnerships with other organizations. National and international partnerships help us to leverage our impact.

Access to a wider pool of resources

By partnering with other organizations, we can access a broader range of resources and exchange with specialized industry stakeholders. Our partnerships strengthen our voice and leverage our impact.

Increased credibility and visibility

Collaboration with reputable partners and policy makers increase the credibility and visibility of our association. This builds trust and confidence, and helps to optimize the framework for a successful industry development.

Improved information exchange

Our partners enable us to access and transfer more knowhow, to provide our stakeholders with privileged information, networking opportunities, international connectivity and access to technologies.

Amplified support for Swiss biotech ecosystem

Our partners help promote and improve our platforms and thus accelerate and amplify the support we can provide to the Swiss biotech stakeholders.



Check out
our partners

The Swiss Biotech Association can reap several benefits from forming partnerships with other organizations. National and international partnerships help us to leverage our impact.



▶ **...optimize framework conditions**

Other associations, councils, committees and policy makers

▶ **...attract, educate and retain talent**

Swiss Biotech Orbit platform and Swiss Biotech Association Academy partners

▶ **...foster international collaborations & trade**

International life science clusters, trade agencies, business hubs, and e.g. the Global Village at the Swiss Biotech Day

▶ **...seek and offer preferential conditions for our members**

Equipment suppliers, insurances, event organizers, analysts, scientific publishers

▶ **...promote competitive advantages**

Promotion agencies, chambers of commerce, Swiss Biotech Report

▶ **...increase credibility & visibility of the industry**


Media, Swiss Biotech Day, Swiss Biotech Success Stories, Swiss Biotech Report, international Swiss pavilions

▶ **...facilitate access to funding and partnering**

Swiss Biotech Ventures platform, investors associations, international investment partners

▶ **...link to specialized stakeholders**

Academia, technology transfer organizations, business development experts



Our
partnerships
help to ...

Income statement

In CHF	2025		2024	
	Expenses	Income	Expenses	Income
Membership fees		1,157,000		1,073,000
International projects		12,396		0
National projects		2,209,497		1,655,238
Website & community platform		2,200		1,600
Swiss Biotech Success Stories		5,000		5,000
Swiss Biotech Report		60,000		58,000
Swiss Biotech Directory		20,830		19,110
Increase/decrease bad debt provision		-18,775		-5,000
Total income		3,448,148		2,806,948
Fees to other associations	26,423		51,977	
International projects	108,449		69,235	
National projects	1,755,117		1,594,422	
Swiss Biotech Success Stories	7,689		10,097	
Decrease tied capital "Swiss Biotech Success Stories"	0		-3,000	
Swiss Biotech Report	81,341		76,174	
Swiss Biotech Directory	39,376		29,889	
Website & community platform	186,983		130,440	
Association activities expense	2,205,377		1,959,234	
Management fees ¹	518,511		376,143	
Accounting & member support	232,297		240,018	
Office rent & administration	45,035		28,635	
Consulting	10,856		23,279	
Public relations	94,526		122,748	
Other operating expenses	901,225		790,823	
Financial income result	24,540		12,624	
Expenses from previous reporting period	0		132	
Tax expenses	1,081		311	
Net profit for the year		315,925		43,824

¹ Management fees related to events and promotional products are directly booked to the respective project

Balance sheet

In CHF	Balance Sheet 31.12.2025		Balance Sheet 31.12.2024	
	Assets	Liabilities	Assets	Liabilities
Assets				
Cash and cash equivalents	732,546		395,347	
Accounts receivable	71,524		71,937	
Accrued income & prepaid expenses	7,035		14,095	
Total assets	811,105		481,379	
Liabilities and equity				
Accounts payable		139,779		170,910
Accrued expenses & deferred income		121,179		76,247
Association equity		131,239		131,239
Tied capital for SBA Sounding Board		10,000		10,000
Retained earnings		92,984		49,160
Net result of the year		315,925		43,824
Total liabilities and equity		811,105		481,379

Auditor's report



Phone +41 44 444 35 55
www.bdo.ch
zurich@bdo.ch

BDO Ltd
Schiffbaustrasse 2
8031 Zurich

Report of the statutory auditor on the limited statutory examination to the general meeting of

Swiss Biotech Association (SBA), Zürich

As statutory auditor, we have examined the financial statements (comprising the balance sheet, operating statement and notes) of Swiss Biotech Association (SBA) for the financial year ended 31 December 2025.

These financial statements are the responsibility of the association board. Our responsibility is to perform a limited statutory examination on these financial statements. We confirm that we meet the licensing and independence requirements as stipulated by Swiss law.

We conducted our examination in accordance with the Swiss Standard on the Limited Statutory Examination. This standard requires that we plan and perform a limited statutory examination to identify material misstatements in the financial statements. A limited statutory examination consists primarily of inquiries of entity personnel and analytical procedures as well as detailed tests of entity documents as considered necessary in the circumstances. However, the testing of operational processes and the internal control system, as well as inquiries and further testing procedures to detect fraud or other legal violations, are not within the scope of this examination.

Based on our limited statutory examination, nothing has come to our attention that causes us to believe that the financial statements do not comply with Swiss law and the articles of association.

Zurich, 2 March 2026

BDO Ltd

Manuel Lüthi

Auditor in charge
Licensed Audit Expert

p.p. (authorised officer) Pirmin Real

Enclosure
Financial statements

BDO Ltd, a limited company under Swiss law, incorporated in Zurich, forms part of the international BDO Network of independent member firms.

Clear focus on what really matters

Aligning our objectives to our mission statement ensures a clear focus on what really matters. However, the priorities may vary and depend on the role and point of view of each stakeholder.



The rapid expansion of our member base provides strong motivation for the Swiss Biotech Association board and management team. At the same time, we seek to constantly improve and challenge ourselves. We invite all stakeholders of the Swiss biotech hub to share their advice, feedback and ideas on how to help promote and strengthen the Swiss biotech industry.

We enhance the visibility of biotech companies

Alentis
THERAPEUTICS

A^e
AltorferEngineering

ATOPIATM

AVANCE
SUPPORTS PREMIER LIFE SCIENCES
ADVISORY BOUTIQUE

basilea

BeOne

bioark

BioConcept

BiOENgINEERING

biopôle

BIO-TECHNOPARK[®]

bucher
biotec

CRAB
CANCER RESEARCH
AND BIOTECHNOLOGY AG

CDR-Life

Cetacea
CLINICAL

chAlron

CLB
CHOOSE LIFE BIOTECH

Cilatus
BIOPHARMA CONSULTING
A ProductLifeGroup Company

CISBIOPHARMA

ClinOps Advisory
TURNER

CMC
& MORE

CPB

csem
FACING THE CHALLENGES OF OUR TIME

CTC

CURATIS

CUTISS
personalized skin

EffRx

EMTEX
LIFE SCIENCE

FLOBIOTECH

Floratek
pharma

GALSER

GENEVANT

GenSearch
TALENTS & EXCELLENCE

Hoffmann
Partner

INNOVALLEX

insideReg
Dedicated to your regulatory success



These members benefit from a cost-effective marketing opportunity, with their logos featured for a year on our communication tools.


Preferential business solutions for our members

In collaboration with business solution partners, the Swiss Biotech Association creates value for its members by leveraging their combined purchasing power, resulting in significant cost savings for running their business. Should you have requirements for additional business solution partners, or like to become one, please let us know (see p. 37).

Swiss Life's pension fund

With the Swiss Biotech Association employee benefits solution, our members join forces and benefit from significantly more attractive risk and cost contributions for occupational benefits with Swiss Life.

SWISS BIOTECH's Life



Helvetia's business insurance

Our members can cover their business risks with Helvetia's individual and modular options. Their 8 in 1 discounted offer includes insurance for movable property, buildings and buildings liability, technical, marine, as well as assistance, legal protection, public and professional liability.




helvetia

Your Swiss Insurer

LubioScience's portfolio

Our members benefit from special discounts on LubioScience's entire portfolio of 4+ million antibodies, proteins, assay kits and lab reagents, and free shipping. They also can access their procurement services and custom services solutions.



LUBIO SCIENCE
THE REAGENT PLATFORM



ProcEurope's laboratory supplies

Our members benefit from significant discounts on laboratory supplies and equipment, e.g. from Fisher Scientific by the European Life Sciences Purchasing Consortium.



BioCentury's market research

A complimentary test access to BioCentury's Intelligence platform, as well as discount on the subscription helps our members' executives and investors solve business-critical decisions and to a better positioning by independent deep-dive analysis, high-quality data, and business intelligence on a global scale.



Springer Nature's leading publications

The world's leading scientific and technical publisher Springer Nature offers our members' subscription discounts between 25% and 50% for some of their most exciting products.



Springer Nature is excited to be part of Swiss Biotech Association. We're celebrating our partnership by offering introductory rates of 25-50% off to new subscribers for access to our most relevant content. Please find an overview of our product portfolio and sample pricing below. Pricing stated below is net.

Your Contact at Springer Nature
 **Beatrice Bourgoin**
Account Manager

SPRINGER NATURE

Swiss Biotech Association board and management

With 659 members, the Swiss Biotech Association has further strengthened its operational structure and ensures nationwide representation across all regions of Switzerland through dedicated regional liaisons.

The board



Patrick Amstutz, PhD
President
CEO Molecular Partners



Anne Marie de Jonge-Schuermans, PhD
Vice President
Global Head Biologics & Injectables Operations
Sandoz



Madiha Derouazi, PhD
Vice President
CEO SwitchKine



Bettina Ernst, PhD
Vice President
CEO BERNINA Bioinvest



Igor Fisch, PhD
Vice President
President Fongit,
CEO & Co-Founder
New Biologix



Filippo Riva
Vice President
Senior Vice President
Vir Biotechnology



David Urech, PhD
Vice President
Chairman Numab

The association supports specialized chapters, platforms, and targeted initiatives and events to strengthen visibility, collaboration and key industry topics across the biotech ecosystem.

The management team



Michael Altorfer, PhD
CEO



Sabine Bamert
Head of communication



Patrick Imwinkelried
Accounting
Wespi & Partner



Annamaria Kauzlaric
Member support
Diagnostics & healthtech
chapters



Natasha Konstantinova
Head talent pool & Swiss
Biotech Association
Academy



Jean-Marc Mezin
Chief Marketing Officer



Maximilien Murone, PhD
Liaison Basel |
Northwestern Switzerland



Fabio Napoletano
Head Business Development
Liaison Bern



Rachel Ougier Simonin
Business processes &
IT infrastructure



Tiziana Rosa, PhD
International relations &
Liaison Svizzera Italiana



Franz Waibel, PhD



Aditya Yellepeddi
Liaison Romandie
Industrial biotech chapter

Supporting the Swiss biotech hub: Objectives 2026

The 2026 objectives of the Swiss Biotech Association are linked to one of our four mission pillars (see p. 12) or enhance the association's financial flexibility and operational effectiveness.



Favorable frameworks

Favorable framework conditions for Swiss biotech companies facilitate access to global talent, funding and innovative technologies, and ensure robust protection of intellectual property, an effective path to regulatory approval and reliable market exclusivity terms.

To strengthen its impact, the Swiss Biotech Association has established a strong network of partners in Switzerland and abroad who share a common objective of optimizing global framework conditions for biotech startups and SMEs (see p. 26–27).

In 2026, we will continue to focus on:

- Promoting the opportunities offered by Switzerland's full re-association with the Horizon Europe R&D program
- Opposing proposals that aim to weaken the international IP framework and risk undermining biomedical innovation
- Helping to shape policies for the life science industry that foster innovation, attract funding, harmonize and accelerate regulatory approvals, and provide reliable market exclusivity periods
- Using our leading position in life sciences R&D to foster international collaboration and help innovate the global healthcare system in international alliances



Talent and finance

In support of the second mission pillar, we develop platforms and tools that enable Swiss-based biotech companies to access international talent, funding and emerging technologies.

Our industry is growing at around five percent annually. This means that each year we need to attract an additional 2,000–3,000 biotech talent, while also replacing those who retire.

Swiss biotech SMEs invest about CHF 2.5 billion in R&D projects every year. While they generate some income through sales and milestone payments, they need to attract about CHF 2–2.5 billion in new funds from global investors to support the industry's current size and growth.

In 2026, we aim to support this by:

- Attracting educational opportunities to the association's Academy platform
- Promoting our Swiss Biotech Orbit platform (p. 9) to expand the Swiss talent pool and match talent with job opportunities in Switzerland
- Promoting our Swiss Biotech Venture platform (p. 8), matching Swiss biotech ventures with global biotech investors and pharma partners
- Organizing Swiss Biotech Day side events for biotech investors and pharma partners
- Negotiating preferential business solutions to help members reduce operating costs



Networking and information exchange

The Swiss Biotech Day expanded in average 30% each year since 2021. We will continue to focus on qualitative growth by enhancing networking and sponsoring formats that foster best practice exchange and support interactions between Swiss biotech CEOs, investors, pharma and leading global advisors/contract research organizations.

In 2026, we plan to strengthen networking opportunities by:

- Increasing the number of specific side events connecting Swiss biotech CEOs, global biotech investors and pharma partners
- Offering for the first time the “Swiss Biotech Showcase”, a focused event for late-stage biotech companies and investors
- Enabling the formation of bilateral biotech communities between Switzerland and strong international biotech hubs
- Expanding Swiss biotech peer-to-peer meetings by organizing the first Swiss biotech meetings for chief scientific and medical officers (CSO, CMO) and for chemistry, manufacturing and quality control (CMC) specialists
- Engaging with various biotech investor groups and supporting the Deep Tech Nation Foundation in developing investment opportunities for institutional investors

Promotion and awareness

For 15 consecutive years, Switzerland has led the Global Innovation Index published by the World Intellectual Property Organization. The Swiss biotech hub is an important factor in this assessment.

To promote the contribution and the value of the 1,700 Swiss-based biotech companies remains the key objective of our fourth mission pillar. While we promote the value of our products and technologies, we also seek to build awareness of the needs of Swiss biotech startups and SMEs to ensure that they can continue to be an essential driver of Switzerland’s innovation power.

To support this, in 2026 we will:

- Publish the digital and print edition of the Swiss Biotech Directory 2026
- Publish the Swiss Biotech Report 2026, highlighting the power of international alliances
- Promote the Access Consortium of Switzerland, Australia, Canada, the UK and Singapore
- Present the Swiss Biotech Success Story Awards to the 2026 laureates

3B Biotech Research Sagl	Antion Biosciences SA	BioLizard SA
3T Biosciences Europe GmbH	Aphaia Pharma AG	BiomedVC AG
4Bases SA	APR Applied Pharma Research SA	Biopôle SA
4G Clinical B.V., Basel branch	Apricot Therapeutics AG	Bioscibex SA
7AlpsBio GmbH	Aptissen SA	Biosynth AG
AB2 Bio Ltd	ARAGEN LIFE SCIENCES LIMITED	Biotech Ventures Advisory Group Sagl
Abbmira Therapeutics AG	Araris Biotech AG	BioVersys AG
abc biopply AG	Aretè Solutions Sagl	BioXpress Therapeutics SA
abcDNA GmbH	Ariceum International AG	Blanc-Labo SA
Aboligix Sàrl	Arphamid Therapeutics GmbH	BLEEDnFIRE Therapeutics
AC Immune SA	ArtBio GmbH	bisc – bihlmann life science communication
Accelsiors AG	ARTIDIS AG	Blueprint Medicines (Switzerland) GmbH
ACM Biosciences AG	Asceneuron SA	Böhler Life Science Advice
ACROBiosystems AG	Aspeya Switzerland SA	Bonetti & Partner GmbH
Activen SA	Atanis Biotech AG	Bright Peak Therapeutics AG
ADC Therapeutics SA	Athebio AG	Bromatech (Suisse) SA
Addex Therapeutics Ltd	Atopia Therapeutics SA	Bucher Biotec AG
ADIENNE Pharma & Biotech SA	Aukera Therapeutics GmbH	Büchi AG
Adiposs SA	Aurealis Therapeutics AG	Bühlmann Laboratories AG
Adolf Kühner AG	Auregen Biotherapeutics SA	Caland SA
Adoram Therapeutics SA	Auxenion Research AG	CALDRE AG
Adularia AG	Avance, Basel GmbH	CalicoBiosystems SA
Advanced Clinical Switzerland GmbH	AVEctivate GmbH	Calliditas Therapeutics Suisse SA
Advesya SA	Avenza Consulting Sarl	Cancer Research and Biotechnology AG
AIC Swiss AG, Zweigniederlassung Frauenfeld	Avrion Therapeutics AG	Canlion AG
aiNET GmbH	AxCelerate Sagl	CanVirex AG
AIPTO TechBio GmbH	axcura AG	Carbogen Amcis AG
Akceso Advisors AG	Axxam SpA	CARREL Avocats SA
Alentis Therapeutics AG	Azafaros Switzerland AG	Catalent Pharma Solutions GmbH
Aleph Farms AG	B SQUARED Sarl	Catalyze Switzerland GmbH
Alira Health AG	Baccinex S.A.	CDR-Life AG
Alitheia Genomics SA	Bachem AG	CEBIS International Sagl
Allegría Therapeutics AG	Baker McKenzie AG	Ceidos SA
Alloy Therapeutics (Switzerland) AG	Baliopharm AG	Celerion Switzerland AG
Almac Clinical Services	Basel Biotech Consulting GmbH	Cellerys AG
Alpha Lyncis SA	Basilea Pharmaceutica Ltd.	Cellestia Biotech AG
AlphaMol Science AG	Bavarian Nordic Berna GmbH	CELLnTEC advanced cell systems AG
AlphaOnco Swiss SA	BC Platforms AG	Cellula Therapeutics SA
Alphastrat GmbH	Becton Dickinson AG	cellvie AG
Alpinuity Bio GmbH	Beech Biotech SA	CellX Biosolutions AG
Altamira Therapeutics AG	BeOne Medicines I GmbH	Celonic AG
Altasciences	BERNINA BioInvest AG	Centenara Labs AG
Altorf Engineering GmbH	BespokExe sarl	Cerbios-Pharma SA
AlveoliX AG	BEYOND GENOMIX SA	Cerdia International GmbH
Amal Therapeutics SA	BIDECO AG	Cetacea Clinical GmbH
Amazentis SA	BigOmics Analytics SA	chAlron SA
Amphasys AG	Bio-Rad Laboratories AG	Chelonia SA
Amphilix AG	Bio-Technologie AG	Chemengineering Switzerland AG
Amporin Pharmaceuticals AG	Bio-Technopark Schlieren-Zürich	Chinsiders GmbH
AMYRA Biotech AG	BioArk SA	Choose Life BioTech SA
AnaPath Services GmbH	BioConcept AG	ChromaCon AG
Anaveon AG	BioConfidant Sàrl	Cilatus Biopharma Consulting AG
AND Biotech AG	BioCopy AG	Cimeio Therapeutics AG
Ansea AG	Bioengineering AG	CIS Biopharma AG
anteris Helvetia AG	Biogen International GmbH	Citeline
	BioLingus IP II GmbH	Citibank, N.A., Sioux Falls, Zurich Branch

Clear Solutions Laboratories AG

ClexBio AG

Clinigen Healthcare Switzerland SARL

Clinipace AG

ClinOps Advisory Turner GmbH

CMC & More GmbH

Complyomics Sarl

Consortia Recruitment Partners GmbH

Coulter Partners

CRA International (Switzerland) GmbH

Cradle Switzerland AG

CRB Group GmbH

CROSS Research SA

CSEM

CSL Behring AG

CTC Resourcing Solutions AG

Culture Collection of Switzerland AG

Curare Swiss AG

Curatis AG

Cure Pharma (Switzerland) GmbH

Curie.Bio

Cutempa Medical AG

CUTISS AG

CxO SA

Cybiome GmbH

Cytiva Europe GmbH

Cytosurge AG

Cyxone Switzerland AG

Dao Tun GmbH

Debiopharm International SA

dEEGtal Insights SA

Delta Medical Promotions AG

Devintec Sagl

DIAMANTE Healthcare Consulting Sagl

Dimericon Therapeutics AG

DiNABIOS AG

Dinaqor AG

DKSH Schweiz AG

DRM Dr. Müller AG

Ectica Technologies AG

Edelweiss Connect GmbH

EffRx Pharmaceuticals SA

ELDICO Scientific AG

Eli Lilly (Suisse) SA

Elionova AG

Elthera AG

Embion Technologies SA

Emtex AG

Enable Biotech AG

Enantios AG

Encelta AG

Ensu GmbH

Enzene Inc.

EPIC Suisse AG

EraCal Therapeutics AG

Ernst & Young AG

EsoCap AG

Eurofins BioPharma Product Testing
Switzerland AG

Eurofins Genomics

Eurofins Professional Scientific Services
Switzerland AG

Eviden AG

EVOLVE AG

Evitria AG

EvlaBio AG

ExcellGene SA

Exeris SA

ExpertInova AG

Expleo Technology Switzerland AG

F. Hoffmann-La Roche AG

Farinha Guedelha Executive Network
Health – GenH

FatiAbGen International GmbH

FB Global Regulatory Consulting and
Coaching Sarl

Fidia Pharma (Switzerland) SA

FimmCyte AG

FinalSpark Sarl

Fischer PreclinTox Consulting

FloBiotech GmbH

Floratek Pharma SA

FluoSphera SA

Fondation EspeRare

Fortrea Switzerland AG

Forty51 Advisors AG

ForX Therapeutics AG

Foundation Immune Engineering for Global
Child and Adolescent Health

Fritz Gyger AG

Future Health Pharma GmbH

Fy Cappa Biologics AG

Galapagos GmbH

Galsler SA

Ganda Business Solutions AG

GBiotech Sarl

Genedata AG

Genesupport SA

GeNeuro SA

Genevant Sciences GmbH

GenSearch Switzerland GmbH

GIO Therapeutics AG

GliaPharm SA

GlycoEra AG

GMP4U GmbH

GMT Fine Chemicals SA

Gnubiotics Sciences SA

Granite Bio AG

GT Gain Therapeutics SA

GTP Bioways CDMO

GXP CONSULTING Switzerland GmbH

Haya Therapeutics SA

HBM Partners AG

headcount AG

Healiva SA

Health Advances GmbH

Healthecon AG

HekeTiss SA

Helsinn Healthcare SA

Helvetica Health Care Sarl

Hemetron AG

HEMEX AG

Hettich AG

HGF GmbH

Hoffmann & Partner AG

HOMAX Advisory

Homburger AG

Horgen Labs GmbH

House of Lab Science AG

Hyperbolic Holdings GmbH

IBR Inc., Institute for Biopharmaceutical
Research

ICARE Laboratoire Switzerland Sarl

ICE Biopharma GmbH

ICON Clinical Research (Switzerland) GmbH

iCure SA

IDEOGEN AG

Idorsia Pharmaceuticals Ltd

IE Life Science Engineering AG

IGI Therapeutics SA

Imbert Consulting Group

Immitra Bio GmbH

ImmunoS Therapeutics AG

ImmunSkills SA

In Virtuo Laboratories SA

Incaptek Sarl

InCephalo AG

Incyte Biosciences International Sarl

Infinity Communications Sarl

Inhalis Therapeutics SA

InkVivo Technologies AG

InnoMedica Holding AG

INNOSIAMO AG

Innovalex Sarl

INOFEA AG

inSEIT AG

InsideReg Sarl

InSphero AG

Institut de formulation des vaccins (CH) SA

Integra Biosciences AG

InterAx Biotech AG

IOntura SA

IPS Biopharma AG

IQone Healthcare Switzerland SA

IQVIA AG

Isospec Analytics SA

J. Lamarck Asset Management SA

Jacobs Switzerland GmbH

Jantar GmbH	Memo Therapeutics AG	NXI Therapeutics AG
Jeffries IP	Menarini Biotech srl	OBaris AG
JFG Life Sciences Stiftung Universität Basel	Merz/Anteis SA	ObelysQ SA
JMP Software, SAS Institute GmbH	MesenFlow Technologies Sàrl	OCCIDENT Group AG
Justin Stindt Consulting AG	metaLead Therapeutics AG	Ocullis Operations Sarl
Juvion Health Sciences SA	metaShape Pharma AG	Oculox Technologies SA
KBI Biopharma SA	MetrioPharm AG	Olgram SA
Kellerhals Carrard	MF Life Sciences GxP Consulting GmbH	OM Pharma Ltd
Kinematica AG	Micro-Sphere SA	OMNI Life Science GmbH
Kisco Sarl	Microsynth AG	OmnilinX Therapeutics AG
Kowa Pharmaceutical Europe AG	MicThera Sagl	Oncodesign Services
KPMG AG	Miltenyi Biotec Swiss AG	Onea Medicines AG
Kronsbjerg GmbH	Mirava Bio Sarl	ONtrack Biomedical AG
Kvalito AG	Mirum Pharmaceuticals AG	Onward Therapeutics SA
Lab Force AG	MOD1 AG	oprandi & partner romandie sa
Labatec Pharma SA	Molecular Partners AG	OptoLumina AG
Labcorp Central Laboratory Services Sàrl	Monte Rosa Therapeutics AG	Oractive Swiss AG
LaForce Business Solutions Sagl	Moonlight AI Sàrl	Oriento SA
LAGOSTA SA	Mosanna Therapeutics AG	Orio Therapeutics SA
Landmark BioVentures AG	MPC Therapeutics SA	Orion Biotechnology Switzerland
LaRive Bio AG	MRGN Advisors Sàrl	Orphan Drug Consulting
Laves-Arzneimittel GmbH	MT-act SA	Oryl Photonics SA
leadXpro AG	MUVON Therapeutics AG	Otten Life Sciences Consulting Sàrl
Lederer & Partner AG	MV BioTherapeutics SA	PALL (SCHWEIZ) GmbH
Legacy Healthcare (Switzerland) SA	Naecture Research Sagl	Paola Valinotti Aostri – Access2Health Consulting
Leman Biotech Lausanne SA	Nagi Bioscience SA	PAREXEL International (CH) AG
Lenz & Staehelin	NanThermix SA	Parithera SA
Life Science Cares Switzerland	Nathalie Jenni Consulting GmbH	PDC Therapeutics SA
LimmaTech Biologics AG	Navignostics AG	Peleven AG
Limula SA	Navis Bio GmbH	PeptART Bioscience GmbH
Linkster Therapeutics AG	NBE-Therapeutics AG	Peptone Switzerland AG
Livinovea GmbH	NCMA Consulting GmbH	Perseo Pharma AG
Lonza AG	NegotiumBio Schweiz GmbH	Phargentis SA
LS Instruments AG	NEMIS TECHNOLOGIES AG	Pharma Consulting ENABLE GmbH
LubioScience GmbH	Neovii Pharmaceuticals AG	PharmaBiome AG
Lucerna Chem AG	Nerai Bioscience	Pharmabotix AG
LUCID Analytics AG	Neurimmune AG	PharmaKorell GmbH
Luminance Health AG	Neurosterix Pharma Sàrl	PharmNDev Experts SA
Lunaphore Technologies SA	Neutrass AG	Pharvaris GmbH
LYO-X AG	Newbiologix SA	Pheida AG
MabTree Biologics AG	Nexco Analytics Sarl	Phialogics AG
Mabylon AG	NexMR AG	Philip Morris Switzerland Sàrl
Macrogen Europe GmbH	Nikon Europe B.V.	Philochem AG
MASY Group GmbH	Ninsun Biotech SA	PHiNE Bio AG
Maxia Strategies GmbH	Noema Pharma AG	Pilatus Biosciences SA
MaxWell Biosystems AG	Nouscom AG	piMed Consulting AG
McArthur and Associates GmbH	NovaGo Therapeutics AG	Planetary SA
MD Bioproducts GmbH	Novaremed AG	PLUS Life Sciences Consulting Sàrl
Mederis di Gaia Piraccini Bellotto	Novartis Pharma AG	PLX Healthcare Services (Schweiz) GmbH
MEDExpansion Sàrl	Novassay SA	PMS Process Management System Sarl
Medistri SA	Novigenix SA	Polaroid Therapeutics AG
Medlabdia AG	NovImmune SA - Light Chain Bioscience	PolyPeptide Group AG
Medscape Education Global	Novochizol SA	Populus Bio Sarl
MedScienceSwiss AG	Nuclidium AG	Porton Pharmaceutical Chemicals GmbH
Medvisis Switzerland AG	Numab Therapeutics AG	Praed Pharmaceuticals AG
MedXCell SA	Xnera Pharma Co., Ltd., Tokyo, Basel Branch	

Prasfarma
Precise Health SA
Preclina Europe GmbH
PreComb Therapeutics AG
Precision Medicine AG
Proceva Biotech AG
Promega AG
Prometheus Life Technologies AG
ProteoMediX AG
Provectis Healthcare AG
PSI CRO AG
Pureos Partners AG
Qanatpharma AG
QBDC GmbH
Quant Biomarkers AG
Quartz Bio SA
Quercis Pharma AG
Quotient Sciences
Rambam AG
RC Tritec AG
RDP Pharma AG
Redbiotec AG
Regen Lab SA
Release Therapeutics SA
REM Analytics SA
Remap Consulting GmbH
Renaldee AG
Repertoire Immune Medicines
(Switzerland) AG
Resea Biotec GmbH
RespAct GmbH
Rhizen Pharmaceuticals AG
RhyGaze AG
Risklick AG
Rockstone Engineering Switzerland Sàrl
Saiba AG
Salmon Pharma GmbH
Salvina Therapeutics AG
Santerus AG
Santhera Pharmaceuticals (Switzerland) AG
Sartorius Stedim Switzerland AG
Schedio SA
SCOPE Consulting GmbH
SEAL Therapeutics AG
Securecell AG
SEED Biosciences SA
Seito Biologics AG
Selmod GmbH
Senn Resources AG
Sferalp SA
SFL Pharma GmbH
SGDL HEALTH SA
SGS Analytics Switzerland AG
SGS Life Sciences Geneva
Shape Biopharmaceuticals AG
Shimadzu Schweiz GmbH

Siegfried Dinamiqs AG
Signal26 Biotherapeutics SA
Skyvor Medical AG
Socorex Isba SA
Solbox GmbH
SOLID Drug Development SA
Solvias AG
Somagenetix AG
Sophia Genetics SA
Sotio Biotech AG
SP Groups SA
SpacePharma SA
SPILLO di Alessandro Di Domizio
Springer Nature Ltd
STALICLA SA
Stallergenes Greer International AG
Stämm Vegh SA
Starlab Schweiz AG
steerBIO GmbH
Stiftung grow
Strategy Consulting Dr. Rudolf K. Sprüngli
Streefkerk Life Sciences Consultancy (SLSC)
Stromal Therapeutics AG
Sumitomo Pharma Switzerland GmbH
SunRegen Healthcare AG
Superlab Suisse AG
Supply Chain Operations SA
Swiss Biotech Center SA
Swiss Cancer Institute
Swiss Consultant-Network GmbH
Swiss Rockets AG
Swiss Stem Cell Foundation
SwitchKine AG
Switzerland Global Enterprise
Swizzard Pharma AG
Sydra AG
Synendos Therapeutics AG
Syneos Health Switzerland GmbH
T-Oncology AG
T3 Pharmaceuticals AG
Tak BioSuisse
Talisto GmbH
Tandem Therapeutics AG
Tane AG
TargImmune Therapeutics AG
TECregen AG
ten23 health AG
Tenpoint Therapeutics GmbH
The Bloc Switzerland AG
The Jackson Laboratory
therainnova AG
TheraPPI Bioscience SA
Thermo Fisher Scientific Biologics Lengnau
Thermo Fisher Scientific Life Technologies
TIBIO Sagl
Tigen Pharma SA

Tigermed Swiss AG
TissueLabs SA
tiventra AG
TOLREMO therapeutics AG
Topadur Pharma AG
TransHeps AG
Trialize AG
TRIDEK-ONE THERAPEUTICS SAS, Paris,
Succursale Lausanne
Trilliume GmbH
UCB Pharma AG/UCB Farchim SA
Ultimate Medicine AG
Umlaut.bio GmbH
Unipharma SA
USP Switzerland AG
Vaccentis AG
Vaderis Therapeutics AG
valuationLAB AG
Vandria SA
Venture Valuation VV AG
Verein Toolpoint for Lab Science
Versameb AG
VILS Switzerland GmbH
Viopas Venture Consulting GmbH
Vir Biotechnology, Inc. (formerly Humabs
BioMed AG)
ViridisGroup Sàrl
Virometix AG
VISCHER AG
Voisin Consulting CH Sàrl
Volv Global SA
VTU Engineering Schweiz AG
Walder Wyss AG
Watson-Marlow AG
Wemedoo AG
Windward Bio AG
Wipro Ltd. Geneva branch
Witec AG
Witt/Kieffer Schweiz AG
WuXi AppTec
Wyss Zurich Foundation
Xcenda Switzerland GmbH
XCubeBio AG
Xemperia SA
Xenomatrix AG
Xlife Sciences AG
YMC Schweiz GmbH
Ymmunobio AG
Yokogawa Innovation Switzerland GmbH
YONI Solutions SA
Ypso Facto Luxembourg S.A
Zambon Biotech SA
Zeta CH AG
Zuger Capital AG



**Swiss Biotech
Association**

Swiss Biotech Association
Löwenstrasse 11
8001 Zürich
Switzerland

T: +41 44 455 56 78

info@swissbiotech.org
swissbiotech.org